|
參考文獻
Abdel WN, Mason RM. (1996) Modulation of neutral protease expression
in human mesangial cells by hyperglycemic culture. Biochem J. 320: 777-783.
Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16: 3797-3804.
Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, García JM, Muñoz A, Esteller M, González-Sancho JM., (2006) Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25: 4116-4121.
Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL. (1997) Vascular endothelial growth factorinduced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 46: 1473-1480.
Akiyama T. (2000) Wnt/beta-catenin signaling. Cytokine Growth Factor. Rev. 11: 273-282.
Alao JP. (2007) The regulation of cyclin D1 degradation: roles in cancer
development and the potential for therapeutic invention. Mol Cancer. 6: 24.
Ali A, Hoeflich KP, Woodgett JR. (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101: 2527-2540.
Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O''Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 282: 27285-27297.
Almeida M, Han L, Martin-Millan M, O''Brien CA, Manolagas SC. (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 282: 27298-27305.
Anderson SS, Tsilibary EC, Charonis AS. (1993) Nonenzymatic
glycosylation-induced modifications of intact bovine kidney tubular
basement membrane. J Clin Invest. 92: 3045-3052.
Armstrong JR, Bonavaud SM, Toole BJ, Yeaman SJ. (2001) Regulation of glycogen synthesis by amino acids in cultured human muscle cells, J. Biol. Chem. 276: 952-956.
Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. (1991) High glucose increases diacylglycerol mass and activates protein kinase C in
mesangial cell cultures. Am J Physiol. 261: F571-F577.
Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ. (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB.Biochem Biophys Res Commun. 314: 197-207.
Bamri-Ezzine S, Ao ZJ, Londono I, Gingras D, Bendayan M. (2003) Apoptosis of tubular epithelial cells in glycogen nephrosis during diabetes.Lab Invest. 83: 1069-1080.
Bank N and Aynedjian HS.,(1993) Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 43: 1306-1312.
Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. (1995) ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 47: 1039-1047.
Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H. (2001) The chromatin remodelling factor Brg-1 interacts with β-catenin to promote target gene activation. EMBO J. 20: 4935-4943.
Benjamin WB, Pentyala SN, Woodgett JR, Hod Y, Marshak D. (1994) Atp citrate-lyase and glycogen synthase kinase-3β In 3t3-l1 cells during differentiation into adipocytes. Biochem. J. 300: 477-482.
Bienz M and Clevers H. (2000) Linking colorectal cancer to Wnt signaling. Cell 103: 311-320.
Bodmer WF. (2006) Cancer genetics: colorectal cancer as a model. J Hum Genet. 51: 391-396.
Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. (1984) Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J. Clin. Invest. 74: 1238-1246.
Booth AA, Khalifah RG, Todd P, Hudson BG. (1997) In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-Amadori glycation pathways. J Biol Chem. 272: 5430-5437.
Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M. (1991) Activation of protein kinase c decreases phosphorylation of c-jun at sites that negatively regulate its DNA-binding activity. Cell 64: 573-584.
Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. (1999) Beta-catenin
regulates the expression of the matrix metalloproteinase-7 in human
colorectal cancer. Am J Pathol. 155: 1033-1038.
Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. (2004) Essential role of BCL9-2 in the switch between β-catenin’s adhesive and transcriptional functions. Genes Dev. 18: 2225-2230.
Brownlee M. (1995) Advanced protein glycosylation in diabetes and aging.Annu Rev Med. 46: 223-234.
Brownlee M. (2001) Biochemistry and molecular cell biology of diabetic
complications. Nature 414: 813-820.
Bucala R, Lee AT, Rourke L, Cerami A. (1993) Transposition of an
Alu-containing element induced by DNA-advanced glycosylation endproducts. Proc Natl Acad Sci U S A. 90: 2666-2670.
Bustos VH, Ferrarese A, Venerando A, Marin O, Allende JE, Pinna LA. (2006) The first armadillo repeat is involved in the recognition and regulation of β-catenin phosphorylation by protein kinase CK1. Proc Natl Acad Sci U S A. 103: 19725-19730.
Carney SL, Wong NL, Dirks J. (1979) Acute effects of streptozotocin diabetes on rat renal function. J Lab Clin Med. 93: 950-961.
Castaño J, Raurell I, Piedra JA, Miravet S, Duñach M, García de Herreros A. (2002) β-catenin N- and C-terminal tails modulate the coordinated binding of adherens junction proteins to β-catenin. J Biol Chem. 277: 31541-31550.
Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 173: 279-289.
Catania JM, Chen G, Parrish AR. (2007) Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol. 292: F905-F911.
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A . (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 94: 13915-13920.
Chen RH, Ding WV, McCormick F. (2000) Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase c. J. Biol. Chem. 275: 17894-17899.
Choo AY, Roux PP, Blenis J. (2006) Mind the GAP: Wnt steps onto the mTORC1 train. Cell 126: 834-6.
Choi HJ, Huber AH, Weis WI. (2006) Thermodynamics of β-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem. 281: 1027-1038.
Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105: 373-379.
Chuang TD, Guh JY, Chiou SJ, Chen HC, Huang JS, Yang YL, Chuang LY. (2007) Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells. Kidney Int. 71: 867-74.
Clevers H. (2006) Wnt/β-catenin signaling in development and disease. Cell 127: 469-480.
Cline GW, Johnson K, Regittnig W, Perret P, Tozzo E, Xiao L. (2002) Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in zucker diabetic fatty (fa/fa) rats. Diabetes 51: 2903-2910.
Cline GW, Johnson K, Regittnig W, Perret P, Tozzo E, Xiao L, Damico C, Shulman GI. (2003) Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker Diabetic Fatty (fa/fa) rats. Diabetes 51: 2903-2910.
Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NR. (2002) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7: 793-803.
Cohen P. (1999) The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Phil. Trans. R. Soc. Lond. B 354: 485-495.
Cohen P and Goedert M. (2004) GSK3 inhibitors: development and therapeutic potential. Nature Reviews Drug Discovery 3: 479-487.
Cole AR, Causeret F, Yaeirgi G, Hastie CJ, McLauchlan H, McManus EJ, Hernandez F, Eickholt BJ, Nikolic M, Sutherland C. (2006) Distinct priming kinases contribute to differential regulation of collapsin response
mediator proteins by glycogen synthase kinase-3 in vivo. J. Biol. Chem. 281: 16591-16598.
Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239.
Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. (2007) Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 26: 1456-1466.
Craven PA, Caines MA, DeRubertis FR. (1987) Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 36: 95-103.
Craven PA and DeRubertis FR. (1989) Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest. 83: 1667-1675.
Craven PA, Davidson CM, DeRubertis FR. (1990) Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes. 39: 667-674.
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem. 77: 94-102.
Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P. (1994) The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line l6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in l6 cells between ras and raf. Biochem. J. 303: 21-26.
Csukai M and Mochly-Rosen D. (1999) Pharmacologic modulation of protein kinase C isozymes: the role of racks and subcellular localisation. Pharmacol Res. 39: 253-259.
Dale TC. (1998) Signal transduction by the Wnt family of ligands. Biochem J. 329: 209-23.
Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pearl LH. (2003) Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J. 22: 494-501.
Daniels DL, Eklof Spink K, Weis WI. (2001) Beta-catenin: molecular plasticity and drug design. Trends Biochem Sci. 26: 672-678.
Daniels DL, Weis WI. (2002) ICAT inhibits β-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell 10: 573-584.
Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. (2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. 279: L429-L438.
Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, Capeau J. (2001) Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259.
Ding VW, Chen RH, McCormick F. (2000) Differential regulation of glycogen synthase kinase 3 beta by insulin and Wnt signaling. J Biol Chem. 275: 32475-32481.
Doble BW and Woodgett JR. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci.116: 1175-1186.
Dominguez and Green JB. (2001) Missing links in gsk3 regulation, Dev. Biol. 235: 303-313
Durvasula RV and Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. (2008) Am J Physiol Renal Physiol. 294: F830-F839.
Eaton S. (1997) Planar polarization of Drosophila and vertebrate epithelia. Curr Opin Cell Biol. 9: 860 -866.
Eisenmann DM, Maloof JN, Simske JS, Kenyon C, Kim SK. (1998) The beta-catenin homolog BAR-1 and LET-60 Ras coordinately regulate the Hox gene lin-39 during Caenorhabditis elegans vulval development. Development. 125: 3667-3680.
Eldar-Finkelman H and Krebs EG. (1997) Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. U.S.A. 94: 9660-9664.
Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. (1999) Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48: 1662-1666.
Eldar-Finkelman H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 8: 126-132.
Ellis V, Behrendt N, Dano K. (1991) Plasminogen activation by receptor-bound urokinase.A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 266: 12752-12758.
Elwing JE, Gao F, Davidson NO, Early DS. (2006) Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol. 101: 1866-1871.
Embi N, Rylatt DB, Cohen P. (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527.
English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH. (1995) Isolation of MEK5and differential expression of alternatively spliced forms. J. Biol. Chem. 270: 28897-28902.
Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184.
Esposito G, Scuderi C, Lu J, Savani C, De FD, Iuvone T, Steardo LJr,Sheen V, Steardo L. (2007) S100B induces tau protein hyperphosphorylation via Dickkopff-1 upregulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med. 12: 914-927.
Fang X, Yu SX, Lu Y, Bast RC Jr, Woodgett JR, Mills GB. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl.
Acad. Sci. U. S. A. 97: 11960-11965.
Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. (2002) Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol. 22. 2099-2110.
Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z. (2007) Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity. J Biol Chem. 282: 11221-11229.
Farr 3rd GH, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman D. (2000) Interaction among gsk-3, gbp, axin, and apc in xenopus axis specification. J. Cell Biol. 148: 691-702.
Fasolini M, Wu X, Flocco M, Trosset JY, Oppermann U, Knapp S. (2003) Hot spots in Tcf4 for the interaction with β-catenin. J Biol Chem. 278: 21092-21098.
Ferrer JC, Favre C, Gomis RR, Fernandez-Novell JM, Garcia-Rocha M, de la Iglesia N. (2003) Control of glycogen deposition, FEBS Lett. 546: 127-132.
Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. (1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262: 14042- 14048.
Fiol CJ, Wang A, Roeske RW, Roach PJ. (1990) Ordered multisite protein phosphorylation. Analysis of glycogen synthase kinase 3 action using model peptide substrates. J. Biol. Chem. 265: 6061-6065.
Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S,Wagle D, Jerums G, Cooper ME. (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 44: 108-114.
Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME . (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17: 1762-1764.
Forde JE and Dale TC. (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 64:1930-1944.
Frame S, Cohen P, Biondi RM. (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7: 1321-1327.
Friedman EA. (1999) Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant. 14: S1-S9.
Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA, Lee ME. (2001) Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem. 276: 17479-17483
Fumo P, Kuncio GS, Ziyadeh FN. (1994) PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line. Am J Physiol. 267: F632-F638.
Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y,
Kikuchi A, Miyazono K, Kato M. (2001) Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol. Cell Biol. 21: 5132-5141.
Gates J and Peifer M. (2005) Can 1000 reviews be wrong? Actin,β-Catenin, and adherens junctions. Cell 123: 769-772.
Giardino I, Edelstein D, Brownlee M. (1994) Nonenzymatic glycosylation invitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest. 94: 110-117.
Godemann R, Biernat J, Mandelkow E, Mandelkow EM. (1999) Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr- Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett. 454: 157-164.
Goldin A, Beckman JA, Schmidt AM, CreagerMA. (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
Graham TA, Weaver C, Mao F, Kimelman D, Xu W. (2000) Crystal structure of a β-catenin/Tcf complex. Cell 103: 885-896.
Greene MW and Garofalo RS. (2002) Positive and negative regulatory role of insulin receptor substrate 1 and 2 (irs-1 and irs-2) serine/threonine phosphorylation, Biochemistry 41: 7082-7091.
Greer EL and Brunet A. (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
Grimes CA and Jope RS. (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling, Prog. Neurobiol. 65: 391-426.
Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589-600.
Guh JY, Huang JS, Chen HC, Hung WC, Lai YH, Chuang LY. (2001) Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am J Kidney Dis. 38: 1096-1104.
Gunter Wolf. (2004) Cell cycle regulation in diabetic nephropathy. Kidney Int. 58: S59-S66.
Ha NC, Tonozuka T, Stamos JL, Choi HJ, Weis WI. (2004) Mechanism of phosphorylation-dependent binding of APC to β-catenin and its role in β-catenin degradation. Mol Cell. 15: 511-521.
Habas R and Dawid IB. (2005) Dishevelled and Wnt signaling: is the nucleus the final frontier? J Biol. 4:2.
Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. (1992) Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 267: 12404-12407.
Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. (1997) Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46: 847-853.
Hannken T, Schroeder R, Zahner G, Stahl RA, Wolf G. (2000) Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol. 11: 1387-1397.
Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B,Woodgett J ,Kilter H, Force T. (2003) Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A. 100: 4610-4615.
Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. (1998) Downregulation of beta-catenin by human axin and its association with the apc tumor suppressor, beta-catenin and gsk3 beta. Curr. Biol. 8: 573-581.
Hart MJ, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P. (1999) The F-box proteinβ-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr Biol. 9: 207-210.
Hardt SE and Sadoshima J. (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res. 90: 1055-1063.
Hartigan JA, Xiong WC, Johnson GV. (2001) Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem Biophys Res Commun. 8: 485-489.
He TC, Chan TA, Vogelstein B, Kinzler KW. (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-45.
He CJ, Zheng F, Stitt A, Striker L, Hattori M, Vlassara H. (2000) Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int. 58: 1931-1940.
He CJ, Koschinsky T, Buenting C, Vlassara H. (2001) Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med. 7: 159-168.
Heidland A, Sebekova K, Schinzel R. (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 38: S100-S106.
Heisenberg CP, Tada M, Rauch GJ, Sayde L, Concha ML, Geisler R, Stemple DL, Smith JC, Wilson SW. (2000) Silberblick/Wnt11 mediates convergent extension movements during zebrafish gastrulation. Nature 405: 76-81.
Hino S, Tanji C, Nakayama KI, Kikuchi A. (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-cateninthrough inhibition of its ubiquitination. Mol Cell Biol. 25: 9063-72.
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and nf-kappab activation. Nature 406: 86-90.
Hoffman BB, Sharma K, Zhu Y, Ziyadeh FN. (1998) Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 54: 1107-1116.
Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM. (2008) Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem. 283: 9224-9230.
Huang JS, Guh JY, Hung WC, Yang ML, Lai YH, Chen HC, Chuang LY. (1999) Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem J. 342: 231-238.
Huber AH, Nelson WJ, Weis WI. (1997) Three-dimensional structure of the armadillo repeat region of β-catenin. Cell 90: 871-882.
Huber AH and Weis WI. (2001) The structure of theβ-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition byβ-catenin. Cell 105: 391-402.
Huelsken J and Behrens J. (2002) The Wnt signaling pathway. J Cell Sci. 115: 3977-3978.
Huelsken J and Birchmeier W. (2001) New aspects of wnt signaling pathways in higher vertebrates, Curr. Opin. Genet. Dev. 11: 547-553.
Hughes K, Ramakrishna S, Benjamin WB, Woodgett JR. (1992) Identification of multifunctional atp-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3. Biochem. J. 288: 309-314.
Hulsken J, Birchmeier W, Behrens J. (1994) E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 127: 2061-2069.
Hunyady L and Catt KJ. (2006) Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 20: 953-70.
Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, Sorcini M, Di Mario U, Pricci F, Pugliese G. (2003) Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol. 14: S264-S270.
Iimura O, Takahashi H, Yashiro T, Madoiwa S, Sakata Y, Asano Y, Kusano E. (2004) Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol. 8: 223-229.
Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S. (1996) N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083.
Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. (1992) Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A. 89: 11059-11063.
Inoki K, Zhu T, Guan KL. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
Ikoulina SE, Ciaraldi TP, Mudaliar s, L. (2002) Carter, K. Johnson and R.R. Henry, Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51: 2190-2198.
Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731.
Ito T, Yorioka N, Yamamoto M, Kataoka K, Yamakido M. (2000) Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol. 11: 1969-1979.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007) Cancer statistics, 2007. CA Cancer J Clin. 57: 43-66.
Jiang, J. and Struhl, G. (1998) Regulation of the Hedgehog and Wingless signaling pathways by the F- box/WD40-repeat protein Slimb. Nature 391: 493-496.
Jope RS and Johnson GV. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
Kagami S, Border WA, Ruoslahti E, Noble NA. (1993) Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest. 69: 68-76.
Kannan N, and Neuwald AF. (2004) Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci. 13: 2059-2077.
Kang J, Dai XS, Yu TB, Wen B, Yang ZW. (2005) Glycogen accumulation in renal tubules, a key morphological change in the diabetic rat kidney. Acta Diabetol. 42: 110-116.
Kidd AR 3rd, Miskowski JA, Siegfried KR, Sawa H, Kimble J. (2005) A α-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling. Cell 121: 761-772.
Kikkawa R, Koya D, Haneda M. (2003) Progression of diabetic nephropathy. Am J Kidney Dis. 41: S19-S21.
Kim E, Arnould T, Sellin LK, Benzing T, Fan MJ, Gruning W, Sokol SY, Drummond I, Walz G. (1999) The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem. 274: 4947-4953.
Kimelman D and Xu W. (2006) β-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25: 7482-7491.
Kobori H, Nangaku M, Navar LG, Nishiyama A. (2007) The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 59: 251-87.
Kohn AD and Moon RT. (2005) Wnt and calcium signaling: beta-catenin independent pathways. Cell Calcium 38: 439-446.
Komers R, Allen TJ, Cooper ME. (1994) Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43: 1190-1197.
Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 100: 115-126.
Korswagen HC, Herman MA, Clevers HC. (2000) Distinctβ-catenins mediate adhesion and signalling functions in C. elegans. Nature 406: 527-532.
Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 94: 6474-6479.
Koya D and King GL. (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866.
Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. (2000) Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC {beta} inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14: 439-447.
Kuramochi J, Arai T, Ikeda S, Kumagai J, Uetake H, Sugihara K. (2006) High Pin1 expression is associated with tumor progression in colorectal cancer. J Surg Oncol. 94:155-160.
Labbe E, Letamendia A, Attisano L. (2000) Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and Wnt pathways. Proc Natl Acad Sci U S A. 97: 8358-63.
Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 272: 17810-14814.
Lechner MS and Dressler GR. (1997) The molecular basis of embryonic kidney development. Mech Dev. 62: 105-120.
Lee J and Kim MS. (2007) The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract. 77 Suppl 1: S49-S57.
Lévy L, Wei Y, Labalette C, Wu Y, Renard CA, Buendia MA, Neuveut C., (2004) Acetylation of β-catenin by p300 regulates β-catenin-Tcf4 interaction. Mol Cell Biol. 24: 3404-3414.
Liberman Z and Eldar-Finkelman H. (2005) Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J. Biol. Chem. 280: 4422-4428.
Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS. (2006) Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol. 17:2812-20.
Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. (1993) cPLA2 is phosphorylated and activated by MAP kinase. Cell 72: 269-278.
Li J and Schmidt AM. (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 272: 16498-16506.
Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY. (2004) Advanced glycation end products activate Smad signaling via TGF-beta dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 18: 176-178.
Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Bogardus C. (1990) Glucose storage is a major determinant of in vivo “insulin resistance” in subjects with normal glucose tolerance, J. Clin. Endocrinol. Metab. 62: 922-927.
Liu BC, Sun J, Chen Q, Luo DD, Ma KL, Ruan XZ. (2004) Effect of irbesartan on angiotensin II-induced hypertrophy of human proximal tubular cells. Chin Med J (Engl). 117: 547-551.
Liu BC, Chen L, Sun J, Huang HQ, Ma KL, Liu H, Liu DG, Zhang XL. (2006) Connective tissue growth factor-mediated angiotensin II-induced hypertrophy of proximal tubular cells. Nephron Exp Nephrol. 103: e16-e26.
Liu Y, Rajur K, Tolbert E, Dworkin LD. (2000) Endogenous hepatocyte growth factor ameliorate chronic renal injury by activating matrix degradation pathways. Kidney int. 58: 2028-2043.
Logan CY and Nusse R. (2004) The Wnt pathway in development and disease. Annu Rev Cell Dev Biol. 20: 781-810.
Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB,Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354: 93-99.
Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. (2005) Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 167: 107-16.
Makita Z, Vlassara H, Cerami A and Bucala R. (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 267: 5133-5138.
Malemud CJ. (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 11: 1696-701.
Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 96: 1603-168.
Malliri A, Rygiel TP, van der Kammen RA, Song JY, Engers R, Hurlstone AF, Clevers H, Collard JG. (2006) The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development .J Biol Chem. 281: 543-8.
Manolagas SC, Almeida M. (2007) Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 21: 2605-2614.
Marshall CB and Shankland SJ. (2006) Cell cycle and glomerular disease: a minireview. Nephron Exp. Nephrol. 102: e39-e48.
McEwen DG and Peifer M. (2000) Wnt signalling: moving in a new direction. Curr Biol.10: R562 -R564.
McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE. (2002) Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.Diabetologia. 45: 268-275.
McLennan SV, Martell SK, Yue DK. (2002) Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 51: 2612-2618.
McManus EJ, Sakamoto KArmit, LJ, Ronaldson L, Shpiro N, Marquez R. and Alessi DR. (2005) Role that phosphorylation of GSK3 plays in insulin and Wnt signaling defined by knockin analysis. EMBO J. 24: 1571-1583.
McRobert EA, Gallicchio M, Jerums G, Cooper ME, Bach LA. (2003) The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. J Biol Chem. 278: 25783-25789.
Meigs TE, Fields TA, McKee DD, Casey PJ. (2001) Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release. Proc. Natl. Acad. Sci. U. S. A. 98: 519-524.
Megy S, Bertho G, Gharbi-Benarous J, Evrard-Todeschi N, Coadou G, Ségéral E, Iehle C, Quéméneur E, Benarous R, Girault JP. (2005) STD and TRNOESY NMR studies on the conformation of the oncogenic proteinβ-catenin containing the phosphorylated motif DpSGXXpS bound to the β-TrCP protein. J Biol Chem. 280: 29107-29116.
Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, Meier M, Gueler F, Fiebeler A, Bahlmann FH, Leitges M, Haller H. (2004) Diminished loss of proteoglycans and lack of albuminuria in protein kinase c-{alpha} – deficient diabetic mice. Diabetes 53: 2101-2109.
Miyagishi M, Fujii R, Hatta M, Yoshida E, Araya N, Nagafuchi A, Ishihara S, Nakajima T, Fukamizu A. (2000) Regulation of Lef-mediated transcription and p53-dependent pathway by associating β-catenin with CBP/p300. J Biol Chem. 275: 35170-35175.
Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, van Ypersele de Strihou C, Kurokawa K. (1998) Renal catabolism of advanced glycation end products:the fate of pentosidine. Kidney Int .53: 416–422.
Mochly-Rosen D and Gordon AS. (1998) Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. 12: 35-42.
Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, Tritschler H, Kasper M, Schwenger V, Hamann A, Dugi KA, Schmidt AM, Stern D, Ziegler R, Haering HU, Andrassy M, van der Woude F, Nawroth PP. (2002) Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51: 3532-3544.
Moon RT, Kohn AD, De Ferrari GV, Kaykas A. (2004) WNT and beta-catenin signalling: diseases and therapies.Nat Rev Genet. 5: 691-701.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790.
Moon RT, Bowerman B, Boutros M, Perrimon N. (2002) The promise and perils of Wnt signaling through β-catenin. Science. 296:1644-1646.
Müller JR, Hocking AM, Brown JD, Moon RT. (1999) Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 18: 7860-7872.
Muller T, Choidas A, Reichmann E, Ullrich A. (1999) Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem. 274: 10173-10183.
Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S. (2000) Glycolaldehyde, a reactive intermediate for advanced glycation end products,plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49: 1714-23.
Nakamura T, Miller D, Ruoslahti E, Border WA. (1992) Production of Extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int. 41: 1213-1221.
Nelson WJ and Nusse R. (2004) Convergence of Wnt, β-catenin, and cadherin pathways. Science 303: 1483-1487.
Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. (1998) Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med. 4: 594-601.
Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T. (2003) Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem. 278: 1380-1387.
Niehrs C. ( 2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469-7481.
Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR.
(2000) Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes. 49: 263-271.
Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemia damage. Nature 404: 787-789.
Noh H and King GL. (2007) The role of protein kinase C activation in diabetic Nephropathy Kidney International 72: S49-S53.
Nusse R. (2001) An ancient cluster of Wnt paralogues. Trends Genet. 17: 443.
Nusse R. (2005) Wnt signaling in disease and development. Cell Res. 15: 28-32.
Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ. (2003) Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871.
Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ. (2008) CDK/GSK-3 inhibitors as therapeutic agents for parenchymal diseases. Kidney Int.73: 684-90.
O’Donnell MP, Kasiske BL, Keane WF. (1988) Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J. 2: 2339-2347.
Ohshiro Y, Ma RC, Yasuda Y, Hiraoka-Yamamoto J, Clermont AC, Isshiki K, Yagi K, Arikawa E, Kern TS, King GL. (2006) Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase c{beta}-null mice. Diabetes 55: 3112-3120.
Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, CooperME. (2001) Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor receptorfor advanced glycation end products (RAGE). J Clin Invest. 108: 1853-1863.
O''Shea JJ. (1997) Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7: 1-11.
Otero K, Martínez F, Beltrán A, González D, Herrera B, Quintero G, Delgado R, Rojas A. (2001) Albumin-derived advanced glycationend-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem. J. 359: 567-574.
Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, Uchida K. (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem. 274: 18492-18502.
Pang R, Yuen J, Yuen MF, Lai CL, Lee TK, Man K, Poon RT, Fan ST, Wong CM, Ng IO, Kwong YL, Tse E. (2004) PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23: 4182-4186.
Papadopoulou, D., Bianchi, M. W. and Bourouis, M. (2004) Functional studies of shaggy/glycogen synthase kinase 3 phosphorylation sites in Drosophila melanogaster. Mol. Cell. Biol. 24: 4909-4919.
Parving HH, Hommel E, Smidt UM. (1998) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ. 297: 1086-91.
Peifer M and Polakis P. (2000) Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 287: 1606-1609.
Perico N, Benigni A, Gabanelli M, Piccinelli A, Ròg M, De Riva C, Remuzzi G. (1992) Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41: 533-538.
PKC-DRS2 Group, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. (2006) Effect of ruboxistaurin on visual Loss in patients withDiabetic retinopathy.Ophthalmology 113: 2221-2230.
Polakis P. (2000) Wnt signaling and cancer. Genes Dev. 14: 1837-1851.
Pokutta S. and Weis WI. (2000) Structure of the dimerization and β-catenin-binding region of β-catenin. Mol Cell. 5: 533-543.
Prevot D, Soltesz Z, Abello V, Wanecq E, Valet P, Unzeta M, Carpene C. (2007) Prolonged treatment with aminoquanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats. Pharmacol Res. 56: 70-79.
Prud''homme B, Lartillot N, Balavoine G, Adoutte A, Vervoort M. (2002) Phylogenetic analysis of the Wnt gene family. Insights from lophotrochozoan members. Curr Biol. 12: 1395.
Pugliese G, Pricci F, Iacobini C, Leto G, Amadio L, Barsotti P, Frigeri L, Hsu DK, Vlassara H, Liu FT, Di Mario U. (2001) Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 15: 2471-2479.
Puig O and Tjian R. (2006) Nutrient availability and growth: regulation of insulin signaling by dFOXO/FOXO1. Cell Cycle 5: 503-505.
Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, Lyons TJ, Jenkins AJ, Baynes JW, Thorpe SR. (1997) Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. J Biol Chem. 272: 17473-17479.
Reya T and Clevers H. (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850.
Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR. (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52: 588-595.
Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb MH. (1993) Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 268: 5097-5106.
Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. (1992) Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int. 41: 107-114.
Roura S, Miravet S, Piedra J, García de Herreros A, Duñach M. (1999) Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem. 274: 36734-36740.
Ruan X and Arendshorst WJ. (1996) Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats.Am J Physiol Renal Physiol. 270: F945-F952.
Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstätter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G. (2007) Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int. 71: 325-35.
Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P. (1980) Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur. J. Biochem. 107: 529-537.
Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. (2001) Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC. Nat Cell Biol. 3: 793-801.
Ryves WJ, Dajani R, Pearl L, Harwood AJ. (2002) Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290: 967-972.
Sadot E, Simcha I, Shtutman M, Ben-Ze''ev A, Geiger B. (1998) Inhibition of beta-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A. 95: 15339-15344.
Saito Y, Vandenheede JR, Cohen P. (1994) The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem. J. 303: 27-31.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 42: 1050-65.
Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. (2006) Crystal structure of a β-catenin/BCL9/Tcf4 complex. Mol Cell.24: 293-300.
Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. (2001) Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 61: 7318-7324.
Schaffer B, Wiedau-Pazos M, Geschwind DH. (2003) Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. Gene 302: 73-81.
Scharnagl H, Stojakovic T, Winker K, Rosinger S, Marz W, Boehm BO. (2007) The HMG-Co A reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endorcrinol Diabetes 115: 372.
Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, Stefan N, Humpert P, Fritsche A, Stumvoll M, Schleicher E, Haring HU, Nawroth PP, Bierhaus A. (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52: 621-633.
Seidensticker MJ and Behrens J. (2000) Biochemical interactions in the wnt pathway, Biochim. Biophys. Acta 1495: 168-182.
Shaw RJ and Cantley LC. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
Sheetz MJ and King GL. (2002) Molecular understanding of hyperglycemia''s adverse effects for diabetic complication. JAMA.
288: 2579-88.
Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. (1993) Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 265: E783-E793.
Shikata K, Makino H, Sugimoto H, Kushiro M, Ota K, Akiyama K,
Araki N, Horiuchi S, Ota Z. (1995) Localization of advanced glycation
endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 9: 269-271.
Shimizu H, Julius MA, Giarre M, Zheng Z, Brown AM, Kitajewski J. (1997) Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth Differ. 8: 1349-1358.
Shin S, Rossow KL, Grande JP, Janknecht R. (2007) Involvement of RNA helicases p68 and p72 in colon cancer.Cancer Res. 67: 7572-7578.
Shulman GI, Rothman DL, Jue R, Stein P, DeFronzo PA, Shulman RG. (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by 13c nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322: 223-228.
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D''Amico M, Pestell R, Ben-Ze''ev A. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 96: 5522-5527.
Simm A, Munch G, Seif F, Schenk O, Heidland A, Richter H,
Vamvakas S, Schinzel R. (1997) Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1. FEBS Lett. 410: 481-484.
Solanas G, Miravet S, Casagolda D, Castaño J, Raurell I, Corrionero A, de Herreros AG, Duñach M. (2004) β-Catenin and plakoglobin N- and C-tails determine ligand specificity. J Biol Chem. 279: 49849-49856.
Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 38: 387-394.
Stadeli R, Hoffmans R, Basler K. (2006) Transcription under the control of nuclear Arm/β-catenin. Curr.Biol. 16: R378-R385.
Stern DM, Yan SD, Yan SF, Schmidt AM. (2002) Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev. 1: 1-15.
Sternlicht MD and Werb Z. ( 2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 17: 463-516.
Stoothoff WH, Bailey CD, Mi K, Lin SC, Johnson GV. (2002) Axin negatively affects tau phosphorylation by glycogen synthase kinase 3beta. J Neurochem. 83: 904-913.
Stopper H, Schinzel R, Sebekova K, Heidland A. (2003) Genotoxicity of
advanced glycation end products in mammalian cells. Cancer Lett.
190: 151-156.
Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H. (1995) Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem Biophys Res Commun. 207: 80-88.
Sun J and Jin T. (2008) Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell.Signal 20: 219-229.
Surendran K, McCaul SP, Simon TC. (2002) A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol. 282: F431-F441.
Surendran K and Simon TC. (2003) CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am J Physiol Renal Physiol. 284: F653-F662.
Sutherland C, Leighton IA, Cohen P. (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296: 15-19.
Sutherland C and Cohen P. (1994) The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAPkinase-activated protein kinase-1 in vitro. FEBS Lett. 338: 37-42.
Takafumi I, Noriaki Y, Masao Y, Katsuko K, Michio Y. ( 2000) Effect of glucose on the cellular junction of cultured human peritoneal mesothelial cells. J Am Soc Nephrol. 11: 1969-1979.
Takahashi YF and Sasaguri T. (2007) The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci. 104:293-302.
Tang Y, Liu Z, Zhao L, Clemens TL, Cao X. (2008) Smad 7 stabilize β-catenin binding to E-cadherin complex and promote cell-cell interaction. J Biol Chem. (in press)
Ter Haar, Coll J, Austen DA, Hsiao HM, Swenson L, Jain J. (2001) Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8: 593-596.
Terada Y, Nakashima O, Inoshita S, Kuwahara M, Sasaki S, Marumo F.
(1999) TGF-beta-activating kinase-1 inhibits cell cycle and expression of cyclin D1 and A in LLC-PK1 cells. Kidney Int. 56: 1378-90.
Tetsu O and McCormick F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 48: 111-117.
Thornalley JP. (1996) Advanced glycation and the development of diabetic complications: unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab. 3: 149-166.
Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. (2002) A new nuclear component of the Wnt signalling pathway. Nat. Cell Biol. 4: 367-373.
Tian YC and Phillips AO. (2002) Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly. Am J Pathol. 160: 1619-1628.
Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. (1993) Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol Renal Physiol. 265: F886-F895.
Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S,Ishida M,Ishikawa S, Yasumura K, Koike T. (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42: 579-588.
Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eyssen G, Bruce WR, Giacca A. (2006) Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 147: 1830-1837.
Twigg SM, Cao Z, MCLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME. (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.Endocrinology. 143: 4907-4915.
Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. (2005) The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686-2690.
Verras M and Sun Z. (2005) Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol. Endocrinol. 19: 391-398.
Viberti GC. (1979) Early functional and morphological changes in diabetic nephropathy. Clin Nephrol. 12: 47-53.
Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M. (1996) Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 16: 1759-1769.
Vinson CR, Conover S, Adler PN. (1989) A Drosophila tissue polarity locus encodes a protein containing seven potential transmembrane domains. Nature. 338: 263-264.
Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 91: 11704-11708.
Vlassara H. (1996) Advanced glycation end-products and atherosclerosis. Ann Med. 28: 419-426.
Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ. ( 2002) Inflammatory mediators are induced by dietary glycotoxins,a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 99: 15596-15601.
von Kries JP, Winbeck G, Asbrand C, Schwarz-Romond T, Sochnikova N, Dell''Oro A, Behrens J, Birchmeier W. (2000) Hot spots in β-catenin forinteractions with LEF-1, conductin and APC. Nat. Struct. Biol. 7: 800-807.
Vo N and Goodman RH. (2001) CREB-binding protein and p300 in transcriptional regulation. J Biol Chem. 276: 13505-13508.
Vona-Davis L, Howard-McNatt M, Rose DP., (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes. Rev. 8: 395-408.
Waltzer L and Bienz M. (1999) The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev. 18: 231-246.
Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV, Jope RS. (2002) Direct activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage.Proc.Natl. Acad. Sci. U. S. A. 99: 7951-7955.
Wang K, Zhou Z, Zhang M, Fan L, Zhou X, Qu W, Lincoff AM, Schimdt AM, Topol EJ, Penn MS. (2006) Peroxisome proliferators-activated receptor gamma down-regulated for advanced glycation end products and inhibits smooth uscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther. 317: 37-43.
Wang JP, Zhou ZG, Lin J, Huang G, Zhang C, Yang L, Yuan Y, Zhou M, Hou C, Zhou WD, Peng H., Hagopian WA. (2007) Islet autoantibodies are associated with HLA-DQ genotype in Han Chinese patients with type 1 diabetes mellitus and their relatives. Tissue antigens 70: 369-275.
Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O,Stern D, Schmidt AM. (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 97: 238-243.
Weis WI, Nelson WJ. (2006) Re-solving the cadherin-catenin-actin conundrum. J Biol Chem. 281: 35593-35597.
Welsh GI, C.G. Proud CG. (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eif-2b. Biochem. J. 294: 625-629.
Welsh GI, Stokes CM, Wang XM, Sakaue H, Ogawa H, Kasuga M. (1997) Activation of translation initiation factor eif2b by insulin requires phosphatidyl inositol 3-kinase. FEBS Lett. 410: 418-422.
Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP,Stern DM, D’Agati VD, Schmidt AM. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte. activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 162:1123-1137.
Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G,Schmidt AM,Yan SF. (2006) RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185: 70-77.
Williams B and Schrier RW. (1993) Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest. 92: 2889-2896.
Wilson CL and Matrisian LM. (1996) Matrilysin: An epithelial matrix
metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 28: 123-136.
Williams ME. (2003) New therapies for advanced glycation end product
nephrotoxicity: Current challenges. Am J Kidney Dis. 41: S42-S47.
Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452.
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J. and Harper, J.W. (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13: 270-283.
Wolf G, Neilson EG, Goldfarb S, Ziyadeh FN. (1991) The influence of glucose concentration on angiotensin II-induced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commun. 176: 902-909.
Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. (1992) High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int. 42: 647-656.
Wolf G. (1995) Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury. Miner Electrolyte Metab. 21: 303-316.
Wodarz A and Nusse R. (1998) Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14: 59-88.
Wolf G and Ziyadeh FN. (1999) Molecular mechanisms of diabetic renal
hypertrophy. Kidney Int. 56: 393-405.
Wolf G. (2000) Cell cycle regulation in diabetic nephropathy. Kidney International Supplement. 77: S59-S66.
Wong NA and Pignatelli M. (2002) Beta-catenins--a linchpin in colorectal carcinogenesis? Am J Pathol. 160: 389-401.
Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH. (2001) Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines. Int J Cancer. 95: 108-113.
Woodgett JR. (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9: 2431-2438.
Woodgett JR. (1991) cDNA cloning and properties of glycogen synthase kinase-3. Methods Enzymol. 200: 564-577.
Writing group for the search for diabetes in youth study group, Dabelea D, Bell RA, D’Agostino RB Jr, Imperatore G. Johansen JM, Linder B, Liu LL,Loots B, Marcovina S,Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. (2007) Incidence of diabetes in youth in the United States. JAMA. 298: 2716-2724.
Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. (2003) Structure of a β-TrCP1-Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCF(β-TrCP1) ubiquitin ligase. Mol Cell 11: 1445-1456.
Xia P, Kramer RM, King GL. (1995) Identification of the mechanism for the inhibition of Na+,K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest. 96: 733-740.
Xing Y, Clements WK, Le Trong I, Hinds TR, Stenkamp R, Kimelman D, Xu W. (2004) Crystal structure of a β-catenin/APC complex reveals a critical role for APC phosphorylation in APC function. Mol Cell. 15: 523-533.
Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 269: 9889-9897.
Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol (Berl). 92: 232-241.
Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson BI, Stern DM, Lalla E, DU Yan S, Rong LL, Naka Y, Schmidt AM. (2004) RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res. 2004: 10-20.
Yang L, Lin C, Liu ZR. (2006) P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127: 139-155.
Yang L, Lin C, Zhao S, Wang H, Liu ZR. (2007) Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem. 282: 16811-16819.
Yi F, Brubaker PL, Jin T. (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem. 280: 1457-1464.
Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. (2008) Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells. Endocrinology 149: 2341-2351.
Yiu WH, Pan CJ, Ruef RA, Peng WT, Starost MF, Mansfield BC, Chou JY. (2008) Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int. 73: 716-723.
Yoshiaki K and Kypta R. (2003) Secreted antagonists of the Wnt signaling pathway. J Cell Science 116: 2627-2634.
Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10: 1443-1454.
Zeng G, Apte U, Micsenyi A, Bell A, Monga SP. (2006) Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp. Cell Res. 312: 3620-3630.
Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 4
|